LncRNA SNHG7 Promotes the HCC Progression Through miR-122-5p/FOXK2 Axis

Zhao, Zhengbin; Gao, Jing; Huang, Shuangsheng

doi:10.1007/s10620-021-06918-2

Cited by 12 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Highly expressed SNHG7 is associated with a poor prognosis in colorectal cancer [ 59 ]. A study revealed that SNHG7 promotes the development of HCC by sponging miR-122-5p to regulate FOXK2 [ 24 ]. In our ceRNA, SNHG7 could regulate G6PD through sponge miR-122-5p in HCC; this provides novel insights regarding the SNHG7/miR-122-5p regulatory model.…”

Section: Discussionmentioning

confidence: 99%

“…MiR-122-5p is specifically expressed in the liver to maintain liver homeostasis and metabolism and is also a new marker of liver injury [ 22 , 23 ]. MiR-122-5p has been shown to be a cancer suppressor molecule that inhibits the growth, metastasis, and infiltration of cancer cells in HCC [ 24 , 25 ]. In the ceRNA network, lncRNAs prevent the combination of miRNA and its target gene by binding to the target miRNA, thus upregulating the expression of the mRNA.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Construction of a competing endogenous RNA network to analyse glucose-6-phosphate dehydrogenase dysregulation in hepatocellular carcinoma

et al. 2022

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common malignant tumour with high rates of morbidity and mortality worldwide. Therefore, it is of great significance to find new molecular markers for HCC diagnosis and treatment. G6PD is known to be dysregulated in a variety of tumours. In addition, the ceRNA network plays a crucial role in the occurrence and development of HCC. However, the mechanism by which the ceRNA network regulates G6PD in HCC remains unclear. We used TCGA-LIHC data to analyse the possibility of using G6PD as an independent prognostic marker. UCR, MCR, and ROC analysis were used to analyse the influence of G6PD overexpression on the prognosis of HCC patients. We also analysed the biological function of G6PD, its effect on the immune microenvironment, and drug sensitivity. Finally, we constructed a ceRNA network of lncRNAs/miR-22-5p/G6PD to explore the regulatory mechanism of G6PD. G6PD was highly expressed in HCC, was related to pathological stage and poor prognosis, and could be used as an independent prognostic indicator of HCC. The expression of G6PD was closely related to the immune microenvironment of HCC. In addition, the expression of G6PD in HCC could be regulated by the ceRNA network. Therefore, G6PD can be used as an immunotherapy target to improve the survival and prognosis of HCC patients, and the ceRNA regulatory network of G6PD has potential diagnostic and therapeutic value for HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Construction of a competing endogenous RNA network to analyse glucose-6-phosphate dehydrogenase dysregulation in hepatocellular carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Like miRNAs and circRNAs, lncRNAs can regulate the expression of FOXK2. For example, the lncRNA SNHG7 enhances the development of HCC by sponging miR-122-5p to regulate FOXK2 ( 27 ). This finding suggests that lncRNAs and FOXK2 are involved in the occurrence and development of cancer.…”

Section: Molecular Mechanisms Of Foxk2 Regulationmentioning

confidence: 99%

Regulation and roles of FOXK2 in cancer

2022

View full text Add to dashboard Cite

Forkhead box K2 (FOXK2) is a member of the forkhead box transcription factor family that contains an evolutionarily conserved winged-helix DNA-binding domain. Recently, an increasing number of studies have demonstrated that FOXK2 plays an important role in the transcriptional regulation of cancer. Here, we provide an overview of the mechanisms underlying the regulation of FOXK2 expression and function and discuss the roles of FOXK2 in tumor pathogenesis. Additionally, we evaluated the prognostic value of FOXK2 expression in patients with various cancers. This review presents an overview of the different roles of FOXK2 in tumorigenesis and will help inform the design of experimental studies involving FOXK2. Ultimately, the information presented here will help enhance the therapeutic potential of FOXK2 as a cancer target.

show abstract

“…Decreased tumor metastasis or repression of some carcinogenic signaling pathways, such as the Notch pathway, is also reported in other animal studies ( Sun et al, 2019 ). For instance, several studies assess the role of SNHG7 knockdown on hepatocellular carcinoma (HCC) growth in xenograft mice ( Yang et al, 2019 ; Yao et al, 2019 ; Xie et al, 2020 ; Zhao et al, 2021 ). Yang et al (2019) demonstrate lower tumor volume and percentage of Ki-67-stained HCCLM3 cells and less lung metastasis of HCCLM3 cells in an SNHG7 knockdown mice group compared with the control group.…”

Section: Introductionmentioning

confidence: 99%

“…This finding is reported for various human cancers, for which survival analysis is conducted ( Table 2 ). For example, in three distinct studies that reported survival analyses in HCC patients, among a total of 150 patients, poorer OS time was reported separately for the patients with elevated tissue SNHG7 expression in comparison to those with low levels ( Yang et al, 2019 ; Zhao et al, 2021 ; Yao et al, 2019 ). Additionally, recurrence is predicted to happen in shorter durations and higher rates among patients with high SNHG7 expression ( Zhang et al, 2020c ).…”

Section: Introductionmentioning

confidence: 99%

Oncogenic Roles of Small Nucleolar RNA Host Gene 7 (SNHG7) Long Noncoding RNA in Human Cancers and Potentials

Najafi

Ghafouri‐Fard

Hussen

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are a class of noncoding transcripts characterized with more than 200 nucleotides of length. Unlike their names, some short open reading frames are recognized for them encoding small proteins. LncRNAs are found to play regulatory roles in essential cellular processes such as cell growth and apoptosis. Therefore, an increasing number of lncRNAs are identified with dysregulation in a wide variety of human cancers. SNHG7 is an lncRNA with upregulation in cancer cells and tissues. It is frequently reported with potency of promoting malignant cell behaviors in vitro and in vivo. Like oncogenic/tumor suppressor lncRNAs, SNHG7 is found to exert its tumorigenic functions through interaction with other biological substances. These include sponging target miRNAs (various numbers are identified), regulation of several signaling pathways, transcription factors, and effector proteins. Importantly, clinical studies demonstrate association between high SNHG7 expression and clinicopathological features in cancerous patients, worse prognosis, and enhanced chemoresistance. In this review, we summarize recent studies in three eras of cell, animal, and human experiments to bold the prognostic, diagnostic, and therapeutic potentials.

show abstract

LncRNA SNHG7 Promotes the HCC Progression Through miR-122-5p/FOXK2 Axis

Cited by 12 publications

References 31 publications

Construction of a competing endogenous RNA network to analyse glucose-6-phosphate dehydrogenase dysregulation in hepatocellular carcinoma

Construction of a competing endogenous RNA network to analyse glucose-6-phosphate dehydrogenase dysregulation in hepatocellular carcinoma

Regulation and roles of FOXK2 in cancer

Oncogenic Roles of Small Nucleolar RNA Host Gene 7 (SNHG7) Long Noncoding RNA in Human Cancers and Potentials

Contact Info

Product

Resources

About